Great Lakes Pharmaceuticals

Early Stage Partners II, L.P. participated in the Series B early stage venture capital investment in Great Lakes Pharmaceuticals, a Cleveland-based clinical stage company that is developing B-Lock™, an anti-coagulant catheter lock solution with strong, broad spectrum activity against bacterial and fungal microorganisms known to form biofilm structures in indwelling catheters.

Recent News For Great Lakes Pharmaceuticals

Great Lakes Pharmaceuticals Raises Series B Early Stage Venture Capital Financing

Find Out More About ESP